Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP1A2 | P05177 | 1/20 | 0.62 |
| ▸ | LMNA | P02545 | 2/20 | 0.55 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.55 |
| ▸ | GPR84 | Q9NQS5 | 4/20 | 0.49 |
| ▸ | MEN1 | O00255 | 2/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.43 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.37 |
| ▸ | CA1 | P00915 | 1/20 | 0.36 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.36 |
| ▸ | MAPT | P10636 | 1/20 | 0.36 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.35 |
| ▸ | TSHR | P16473 | 1/20 | 0.34 |
| ▸ | YTHDF3 | Q7Z739 | 1/20 | 0.32 |
| ▸ | YTHDF1 | Q9BYJ9 | 1/20 | 0.32 |
| ▸ | YTHDF2 | Q9Y5A9 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11841644 | 0.88 | CYP1A2 (0.71) | CYP1A2LMNAALDH1A1GPR84MEN1 | |
| Ammonia Solution, Strong SCHEMBL28111982 | 0.86 | CYP1A2 (0.69) | CYP1A2LMNAALDH1A1GPR84MEN1 | |
| SCHEMBL27735725 | 0.82 | CYP1A2 (0.69) | CYP1A2LMNAALDH1A1GPR84MEN1 | |
| SCHEMBL11042365 | 0.81 | CYP1A2 (0.68) | CYP1A2LMNAALDH1A1GPR84MEN1 | |
| SCHEMBL11884800 | 0.80 | CYP1A2 (0.56) | CYP1A2LMNAALDH1A1GPR84MEN1 | |
| SCHEMBL26640809 | 0.79 | CYP1A2 (0.64) | CYP1A2LMNAALDH1A1GPR84MEN1 | |
| SCHEMBL4283121 | 0.79 | CYP1A2 (0.64) | CYP1A2LMNAALDH1A1GPR84MEN1 | |
| SCHEMBL28078211 | 0.79 | CYP1A2 (0.69) | CYP1A2LMNAALDH1A1GPR84MEN1 | |
| SCHEMBL3457903 | 0.78 | ALDH1A1 (0.65) | CYP1A2LMNAALDH1A1GPR84MEN1 | |
| SCHEMBL2516165 | 0.78 | CYP1A2 (0.62) | CYP1A2LMNAALDH1A1GPR84MEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110190267-A1 | PRODRUGS OF OPIOIDS AND USES THEREOF | SHIRE PHARMACEUTICALS, INC. (US) | 2011-08-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110190267-A1 | PRODRUGS OF OPIOIDS AND USES THEREOF | OPRK1, OPRL1, OPRM1 | CYP1A2 24/4885LMNA 4680/4885ALDH1A1 225/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.